10.07.2017 • TopicsAsahi Kaseicaustic sodachlor-alkali

Asahi Kasei: Lower Power Consumption Technology for the Chlor-Alkali Industry

More than 130 plants with combined production capacity of over 25 million t/y...
More than 130 plants with combined production capacity of over 25 million t/y of caustic soda are operated today based on the Asahi Kasei chlor-alkali process technology.

In 1975, Asahi Kasei began the first commercial chlor-alkali production using the membrane electrolysis process. This industrial process for the electrolysis of sodium chloride, used to manufacture caustic soda and chlorine, works without using hazardous material and with lower energy consumption than comparable processes.

Since, Asahi Kasei has strived for technical leadership in the world-wide chlor-alkali industry in the constant developments of membrane electrolysis technology, including the Aciplex-F perfluorosulfonic acid membrane, and the Acilyzer electrolyzer with operation technologies.

Recently, Asahi Kasei showcased the newly developed membrane grade Aciplex F7001X, an energy saving innovation which is to meet the customers’ strong requirements for lower power consumption in the chlor-alkali industry. The innovation will be evaluated in the market in the coming months.

More than 130 plants with combined production capacity of over 25 million t/y of caustic soda are operated today based on the Asahi Kasei chlor-alkali process technology.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.